Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
28 hedge funds and large institutions have $56.7M invested in Cymabay Therapeutics in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
8% more funds holding
Funds holding: 26 → 28 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less capital invested
Capital invested by funds: $75.3M → $56.7M (-$18.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.17M |
| 2 |
VAM
Visium Asset Management
New York
|
+$3.98M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
+$3.6M |
| 4 |
Morgan Stanley
New York
|
+$662K |
| 5 |
SIM
Spark Investment Management
New York
|
+$579K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.96M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.24M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.2M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$983K |
| 5 |
Jennison Associates
New York
|
-$695K |
CBAY Hedge Fund Activity: Q1 2015 in Review
28 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2015, worth a combined $56.7M — down 25% from $75.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CBAY positions and 8 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6.17M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $6.96M sold.
- 28 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2015, up from 26 in Q4 2014.
- Funds reported $56.7M of Cymabay Therapeutics stock for Q1 2015, down 25% quarter-over-quarter.
- 10 funds opened new Cymabay Therapeutics positions in Q1 2015 and 8 closed out, a net change of +2 holders.
- The largest Cymabay Therapeutics buyer in Q1 2015 was Adage Capital Partners, an estimated $6.17M added.
- The largest Cymabay Therapeutics seller in Q1 2015 was Sectoral Asset Management, an estimated $6.96M sold.
Based on aggregated 13F filings for Q1 2015.